References
- Minna J M, Higgins G A, Glastein E J. Cancer of the lung. Cancer: Principles of Oncology, V T. De Vita, S. Helleman, S A. Rosemberg. Lippincot, Philadelphia 1985; 506–597
- Silverberg E, Lubera J A. Cancer statistics CA. Cancer J Clin. 1988; 38: 5–22
- Vincent B C, Chu T M, Lane W W. The value of carcinoembryonic antigen in patients with carcinoma of the lung. Cancer 1979; 11: 685–691
- Buccheri G F, Violante B, Sartoris A M, Ferrigno D, et al. Clinical value of multiple biomarker assay in patients with bronchogenic carcinoma. Cancer 1986; 51: 2389–2396
- Mizushima Y, Hirata H, Izumi S, et al. Clinical significance of the number of positive tumour markers in assisting the diagnosis of lung cancer with multiple tumour marker assay. Oncol 1990; 47: 43–48
- Erbert W, Kayser K, Buelzebruck H, et al. The measurement of SCC antigen in squamous cell carcinoma of the lung. Tumour Marker Oncol. 1988; 3: 35–44
- Cooper E H. Neuron-specific enolase. Int J Biol Markers 1994; 9: 205–210
- Gomm S A, Keevil B G, Thatcher N, et al. The value of tumour markers in lung cancer. Br J Cancer 1988; 58: 797–804
- Bombardieri E, Seregni E, Bogni A, Ardit S, Belloli S, et al. Evaluation of cytokeratin 19 serum fragments (CYFRA 21—1) in patients with lung cancer: results of a multicenter trial. Int J Biol Markers 1994; 9: 89–95
- Pujol J L, Grenier J, Daures J P, Daver A, et al. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21—1 immunoradiometric assay as a marker of lung cancer. Cancer Res 1993; 53: 61–66
- Moll R. Cytokeratins in the histological diagnosis of malignant turnours. Int. J. Biol. Markers 1994; 9: 63–69
- Bodenmuller H, Donie F, Kaufman M, Banauch D. The tumours markers TPA, TPS, TPA cyk and CYFFU 21—1 react differently with keratins 8, 18 and 19. Int. J. Biol. Markers 1994; 9: 70–74